Cadrenal Therape SEC Filings

Cadrenal Therapeutics is issuing 207,374 shares of common stock in a registered direct offering at $10.85 per share, for gross proceeds of $2,250,007.90. In a concurrent private placement, the same investors receive unregistered common warrants to buy up to 414,748 additional shares at an exercise price of $10.60 per share.

The company expects net proceeds of approximately $1.9 million, which it plans to use for working capital and general corporate purposes. After the offering, 2,338,127 shares of common stock will be outstanding, and new investors will see immediate dilution of $8.44 per share based on an as adjusted pro forma net tangible book value of $2.41. Cadrenal also discloses that its limited capital and financing needs raise substantial doubt about its ability to continue as a going concern without further funding.

CVKD is updating its at-the-market common stock offering program under an existing shelf registration. The company has sold an aggregate of $10,005,300 of common stock through its sales agreement with H.C. Wainwright & Co. as of this prospectus supplement. This update reduces the amount available under the November 18, 2025 prospectus supplement by $2,250,007.90, leaving $569,717 of common stock that can still be sold under that supplement. CVKD’s common stock trades on the Nasdaq Capital Market under the symbol CVKD, and the last reported sale price was $11.00 per share on December 12, 2025.

Cadrenal Therapeutics, Inc. filed a prospectus supplement supporting its existing at-the-market equity program, allowing the offer and sale of up to $3,438,062 of its common stock through H.C. Wainwright & Co. as sales agent. These sales are made under an already effective Form S-3 shelf registration statement. As of the same date, the company has sold an aggregate of $9,386,964 of common stock under this at-the-market agreement. H.C. Wainwright is entitled to a 3.0% commission on the gross sales price of shares sold, and the company may suspend or terminate the program subject to the terms of the agreement.

Cadrenal Therapeutics, Inc. is updating its at-the-market equity program to offer and sell up to $3,438,062 of common stock through H.C. Wainwright & Co. as sales agent or principal. Based on an assumed price of $11.61 per share, this corresponds to up to 296,129 shares, which would raise Cadrenal’s common stock outstanding from 2,075,845 to as many as 2,371,974 shares if fully sold. Wainwright will receive a 3.0% sales commission on gross proceeds. The company plans to use any net proceeds for working capital and general corporate purposes, including potential acquisitions, licensing or investments in product candidates or other intellectual property, and possible repurchases of securities. The filing highlights that the ATM structure may lead to price variation and potential dilution for new and existing shareholders.

Cadrenal Therapeutics (CVKD) submitted an 8-K announcing it furnished a press release with financial information for the quarter ended September 30, 2025, under Item 2.02.

The company states this information, including Exhibit 99.1, is furnished and not deemed filed, and is not incorporated by reference into other SEC filings. The press release was issued on November 10, 2025.

Cadrenal Therapeutics (CVKD) reported a larger year-to-date loss and flagged liquidity risk. Net loss was $2.69 million for Q3 2025 and $10.20 million for the nine months ended September 30, 2025. Operating expenses for the nine months rose to $10.40 million, driven by higher G&A of $6.96 million (up 73%) and R&D of $3.43 million (up 29%). Interest and dividend income contributed $0.20 million year to date.

Cash and cash equivalents were $3.86 million as of September 30, 2025, after $10.03 million used in operating activities year to date. Management states these factors raise substantial doubt about the company’s ability to continue as a going concern. To bolster liquidity, Cadrenal raised $3.83 million net via its ATM during the nine months and a further approximately $0.22 million net after quarter-end.

On September 12, 2025, Cadrenal acquired eXIthera assets, including frunexian (EP-7041) and EP-7327. The company paid $50,000 at closing and expensed $151,216 in transaction costs, with contingent milestones of up to $15 million, a 2% royalty on future net sales, and 50% of royalties received under the Haisco license.

Cadrenal Therapeutics (CVKD) reported insider transactions by its Chief Financial Officer, Matthew K. Szot. He sold 1,800 shares of common stock on October 24, 2025, and 1,800 shares on October 27, 2025, each at $13.99 per share, coded as open‑market sales (S).

The filing states these trades were executed under a Rule 10b5-1 trading plan adopted on May 9, 2025. Following the reported sales, the officer directly beneficially owns 9,933 shares.

Cadrenal Therapeutics (CVKD): CEO/Chairman Quang Pham reported open‑market sales under a Rule 10b5‑1 plan. On 10/24/2025, he sold 1,129 shares of common stock at a weighted average price of $14.03, with trades ranging from $13.99 to $14.10. On 10/27/2025, he sold 1,315 shares at a weighted average price of $13.99, with trades ranging from $13.99 to $14.00. The trading arrangement was adopted on May 9, 2025.

Following these transactions, direct beneficial ownership was 197,404 shares after the first sale and 196,089 shares after the second. He also holds 200,000 shares indirectly through The PVBQ Living Trust, for which he serves as trustee with sole voting and disposition power.

Cadrenal Therapeutics (CVKD) reported an insider transaction by its Chief Financial Officer. On 10/09/2025, the CFO sold 1,693 shares of common stock at $13.99, and on 10/13/2025, sold 1,800 shares at $14.07, in each case under a Rule 10b5-1 trading arrangement. Following these sales, the CFO directly beneficially owned 13,533 shares.